Drug Profile
Docetaxel liposomal - Insys Therapeutics
Alternative Names: LE-DT; Liposome encapsulated docetaxel - Insys Therapeutics; Liposome entrapped docetaxel - Insys TherapeuticsLatest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator NeoPharm Inc
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pancreatic cancer; Prostate cancer
Most Recent Events
- 31 Dec 2011 NeoPharm Inc completes a phase II trial in Pancreatic cancer in USA (NCT01186731)
- 01 Jun 2010 Phase-II clinical trials in metastatic, castrate resistant Prostate cancer in USA (IV)
- 21 Apr 2010 Phase-II clinical trials in metastatic or advanced Pancreatic cancer, first-line therapy, in USA (IV)